Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.

Tintelnot J, Baum N, Schultheiß C, Braig F, Trentmann M, Finter J, Fumey W, Bannas P, Fehse B, Riecken K, Schuetze K, Bokemeyer C, Rösner T, Valerius T, Peipp M, Koch-Nolte F, Binder M.

Mol Cancer Ther. 2019 Apr;18(4):823-833. doi: 10.1158/1535-7163.MCT-18-0849. Epub 2019 Mar 1.

PMID:
30824613
2.

PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).

Decker S, Finter J, Forde AJ, Kissel S, Schwaller J, Mack TS, Kuhn A, Gray N, Follo M, Jumaa H, Burger M, Zirlik K, Pfeifer D, Miduturu CV, Eibel H, Veelken H, Dierks C.

Mol Cancer Ther. 2014 May;13(5):1231-45. doi: 10.1158/1535-7163.MCT-13-0575-T. Epub 2014 Mar 21.

Supplemental Content

Loading ...
Support Center